TB Screening LFA
Tuberculosis
DevelopmentActive
Key Facts
About DiagMetrics
DiagMetrics is an innovative diagnostics company developing a proprietary Mask-Based Diagnostic (MBD™) platform that collects exhaled breath condensate (EBC) for non-invasive testing. With a strong intellectual property portfolio including multiple issued and pending patents, the company is initially targeting rapid screening for tuberculosis and respiratory viruses (SARS/Flu/RSV) using lateral flow assays and advanced biosensors. Backed by NIH RADx funding and a partnership with MilliporeSigma, DiagMetrics aims to democratize diagnostics by making testing as simple as breathing, with applications extending to chronic disease monitoring and oncology.
View full company profileTherapeutic Areas
Other Tuberculosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine TB Vaccine | Vaxine | Preclinical |
| Isoniazid Oral Solution, USP | CMP Pharma | Approved |
| Tuberculosis Program | Fimbrion Therapeutics | Preclinical |
| Undisclosed Program | Crestone | Preclinical |
| Tuberculosis Diagnostic | GenEndeavor | Research/Exploratory |
| RGFields for Tuberculosis | Anapole Technologies | Pre-clinical |
| Tuberculosis Nanobody | VicuTec Biologicals | Pre-clinical |
| Not specified on provided pages | Cadila Pharmaceuticals | Commercial (World's First Claim) |
| TB Diagnostic & Drug Discovery | Avesthagen | Research/Discovery |
| ALF Platform | Senzo | Pre-clinical |
| Satiro Tablets | KYORIN Pharmaceutical | Registration |